|
|
6330 Nancy Ridge Drive, Suite 103
San Diego, CA 92121 USA
phone:858- 222-8041
fax:858-866-0482
|
|
| Symbol |
APRI |
| Exchange |
Nasdaq |
| Founded |
1987 |
| Employees |
34 |
|
|
| www.apricusbio.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Drug delivery technology focused on dermatology, sexual dysfunction, and cancer. |
|
| Management |
| Bassam B. Damaj, Ph.D, President & Chief Executive Officer; Vivian Liu, Executive Vice President; Mark Westgatem Vice President & Chief Financial Officer; Edward Cox, Vice President Investor Relations & Corporate Development |
| |
|
|
|
|
|
|
|
| Keywords |
| dermatology, sexual dysfunction, cancer, drug delivery, oncology, CRO |
|
|
|
| Description |
|
Backed by a solid, revenue generating CRO business, Bio-Quant, Inc. and its NexMed
USA subsidiary, Apricus Bio has leveraged the flexibility of its proven NexACT drug delivery technology to enable multi-route administration of new and improved
compounds across numerous therapeutic classes. Future growth will be driven primarily
through out-licensing of this technology for the development and commercialization
of such compounds to pharmaceutical and biotechnology companies, worldwide.
Concurrently, the Company is seeking to monetize its existing product pipeline, including
compounds from pre-clinical through Phase 3, currently focused on dermatology, sexual
dysfunction and cancer. |
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
